As shown in Supplementary Table S1, among SS-L patients, those bearing the functional LILRA3 +/+ variant demonstrated increased prevalence of anti-Ro/SSA and/or anti-La/SSB antibodies compared to those with the homozygous or heterozygous deletion (89% vs. 60%, p = 0.03, respectively), as well as a trend towards increased LILRA3 serum levels among all SS patients bearing the wild type polymorphism (Supplementary Figure S3). This evidence concerns the gene SSB and synovial sarcoma.